MedPath

Celecoxib

Generic Name
Celecoxib
Brand Names
Celebrex, Elyxyb, Seglentis
Drug Type
Small Molecule
Chemical Formula
C17H14F3N3O2S
CAS Number
169590-42-5
Unique Ingredient Identifier
JCX84Q7J1L
Background

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.

Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.

Indication

Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.

It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.

Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.

Associated Conditions
Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Associated Therapies
-
Clinical Trials
Related News

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer

Phase 1
Active, not recruiting
Conditions
Bladder Cancer
Interventions
Drug: Celecoxib
Drug: Gemcitabine
Drug: Cisplatin
First Posted Date
2016-09-01
Last Posted Date
2024-05-28
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
15
Registration Number
NCT02885974
Locations
🇺🇸

Baylor Clinic, Houston, Texas, United States

🇺🇸

Harris Health System - Smith Clinic, Houston, Texas, United States

Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy

Phase 2
Terminated
Conditions
Spinal Muscular Atrophy (SMA)
Interventions
Drug: celecoxib
First Posted Date
2016-08-23
Last Posted Date
2020-10-19
Lead Sponsor
Hugh McMillan
Target Recruit Count
1
Registration Number
NCT02876094
Locations
🇨🇦

Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair

Phase 4
Completed
Conditions
Rotator Cuff Tear
Interventions
Drug: Celecoxib
Drug: Ibuprofen
Drug: Tramadol
First Posted Date
2016-07-29
Last Posted Date
2016-07-29
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
180
Registration Number
NCT02850211

Celecoxib for Thyroid Eye Disease

Phase 2
Terminated
Conditions
Thyroid Eye Disease
Interventions
Drug: Celecoxib
Drug: artificial tears
First Posted Date
2016-07-27
Last Posted Date
2020-07-31
Lead Sponsor
Johns Hopkins University
Target Recruit Count
7
Registration Number
NCT02845336
Locations
🇺🇸

Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States

Pre-Prostatectomy Celecoxib or Placebo

Phase 2
Terminated
Conditions
Adenocarcinoma of the Prostate
Prostate Cancer
Interventions
Drug: Celecoxib
Drug: Placebo
First Posted Date
2016-07-21
Last Posted Date
2017-04-28
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
34
Registration Number
NCT02840162
Locations
🇺🇸

Portland VA Medical Center, Portland, Oregon, United States

🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

Phase 1
Withdrawn
Conditions
Melanoma
Neoplasm Metastasis
Sarcoma
Neoplasms, Germ Cell and Embryonal
Interventions
Drug: decitabine (DAC)
Drug: Tetrahydrouridine (THU)
Drug: Celecoxib
First Posted Date
2016-07-21
Last Posted Date
2018-07-05
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT02839694

Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion

Phase 4
Conditions
Pain
Interventions
Drug: Tramadol
Drug: Celecoxib
Drug: Placebo 2
Drug: Placebo 1
Procedure: IUD
First Posted Date
2016-07-11
Last Posted Date
2019-04-08
Lead Sponsor
Cairo University
Target Recruit Count
210
Registration Number
NCT02827487
Locations
🇪🇬

Cairo University Hospitals, Cairo, Egypt

Perioperative Use of a Selective COX2 Inhibitor in Patients Undergoing Elective Colorectal Surgery: the Effect on Post-operative Bowel Motility and Post-operative Pain

Not Applicable
Conditions
Prevention of Post Operative Ileus
Interventions
Drug: Placebo
Drug: Celecoxib
First Posted Date
2016-06-03
Last Posted Date
2016-06-03
Lead Sponsor
Sheba Medical Center
Target Recruit Count
100
Registration Number
NCT02790203

Evaluation of Perioperative Celecoxib for Hip Arthroscopy

Not Applicable
Completed
Conditions
Hip Labral Tears
Interventions
Drug: placebo
Drug: Celecoxib
First Posted Date
2016-05-20
Last Posted Date
2019-09-23
Lead Sponsor
Northwestern University
Target Recruit Count
98
Registration Number
NCT02779166

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

First Posted Date
2016-05-12
Last Posted Date
2021-10-05
Lead Sponsor
University of Ulm
Target Recruit Count
10
Registration Number
NCT02770378
Locations
🇩🇪

University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy